Don’t reinvent the wheel. The ACR Committee on Rheumatologic Care offers members an updated slate of template letters to help appeal insurance denials for common off-label rheumatology treatments.
Articles by From the College
FTC Bans Noncompete Agreements: What Rheumatologists Need to Know
The ACR applauds the FTC’s recent ban on most noncompete agreements. The ruling is a step in the right direction toward a more competitive market for healthcare workers and their services.
Physician Practice Input Needed by June 30 to Inform Accurate Physician Payment
A survey in June, led by the AMA but endorsed by the ACR, will collect data on practice costs and hours of patient care. Practices selected to participate will be contacted via email and U.S. Postal Service, and are encouraged to respond.
Commercial Payers Update Reimbursement for Underwater Infliximab Biosimilars
Three commercial health insurance payers have increased reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
Methylprednisolone & Methotrexate: Codes & Billing Updated
As of April 1, HCPCS codes for methylprednisolone have changed. The ACR is working with the CMS to determine how rheumatologists should bill Medicare corrrectly.
Advocate from Home for Medicare Payment Reform on Capitol Hill
As ACR leaders and volunteers visit Capitol Hill to advocate for stabilizing Medicare physician payment rates, you can join the effort from anywhere. Send your lawmakers a message today through the Legislative Action Center.
An Inside Look at the Advocacy Leadership Conference
At this year’s Hill Day, attendees will receive in-depth training on Medicare reimbursement and hear from Rep. Larry Bucshon, MD, (R-Ind.) about his perspective on the issue as a physician in Congress.
Advocacy Leadership Conference to Support Inflation-Linked Medicare Payment Increases
On May 7, ACR leaders from the Board of Directors, committees and more will to go to Capitol Hill and ask lawmakers to support legislation that would stabilize Medicare reimbursement for physicians.
CMS Updates the Medicare Conversion Factor
The Consolidated Appropriations Act, 2024 increased the Medicare conversion factor by 1.68% effective March 9, bringing it to $33.2875 for March 9–Dec. 31, 2024.
UnitedHealthcare Updates Reimbursement for Infliximab Biosimilars
On April 1, UnitedHealthcare updated reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 92
- Next Page »